drugset / Trial / NCT05992584
Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
NaSingle-groupOpen-labelTreatment
Summary
This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).
Timeline
- Start
- 2023-08-10
- Primary completion
- 2026-01-09
- Completion
- 2026-08-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |